China & Geopolitical Strategic Advisory

25 years of China.
360 degrees of
expert coverage.

Fountainhead Global Partners provides 360-degree strategic advisory on China and geopolitical risk — led by a principal with 25 years of legal, political, and commercial experience across China and Hong Kong, and supported by a team of specialists spanning technology, supply chain, regulatory, national security, and sanctions and trade architecture.

Our Services Our approach
What makes us different
Chinese-language primary sources
and substantive real China experience
Real lived China experience, understanding of culture, business practices coupled with deep dive into patent filings, corporate registry disclosures — in the original language, before they reach English-language analysts.
Legal authority
PRC and Hong Kong
Legal and Political System
Our founding principal brings 25 years of legal dispute and political experience across China and Hong Kong — including front-line engagement as a member of the legislature during the most consequential period in Hong Kong's modern history. Not commentary — counsel.
360-degree coverage
Technology · Supply chain
Policy · National security
Our team of China specialists spans technology, supply chain, regulatory, and national security — covering every dimension of a China-related decision from a single point of contact, rather than requiring clients to assemble and reconcile multiple advisers.
Discover

"China risk does not sit neatly within a single discipline. Neither should the advice."

Fountainhead Global Partners
Boston · New York · London
Who We Are

25 years of China.
360 degrees of
expert coverage.

Fountainhead Global Partners delivers 360-degree strategic advisory on China and geopolitical risk to life sciences corporations, pharmaceutical and biotechnology firms, financial institutions, investment funds, and corporations facing complex cross-border regulatory and strategic decisions. Our work spans the full spectrum of China and geopolitical risk — political, commercial, technical, regulatory, and sanctions-related — because our clients' decisions rarely sit neatly within a single discipline.

We are led by a principal with 25 years of experience in legal disputes and political engagement across China and Hong Kong — one of the deepest individual track records available in the market. Around that anchor, we have assembled a team of China specialists whose expertise spans technology, supply chain, national security, and regulatory, enabling us to advise on complex, multi-dimensional China questions from a single point of contact.

Our two primary client verticals are life sciences and pharmaceutical — where China's innovation pipeline and regulatory architecture create unique complexity — and financial institutions, where banks, private equity, and hedge funds face an expanding set of China-related counterparty, investment, and regulatory questions that their internal teams are rarely equipped to answer with primary-source rigour.

Primary FocusLife Sciences · Financial Institutions · Geopolitical & Regulatory Risk
ScopeChina and geopolitical risk decisions by US, European, and international clients
CoverageOperating across Boston, New York, and London
01
Chinese-Language Intelligence
We access patent databases, corporate registries, drug regulator filings, state investor disclosures, and institutional affiliation records — in the original language. This is not translation. It is analysis that begins where English-only research ends.
02
PRC Legal and Political Authority
Our founding principal brings 25 years of direct engagement with the PRC legal and political system — spanning high-profile commercial disputes, cross-border arbitration, capital markets transactions, and front-line political experience as a member of Hong Kong's legislature. This is not theoretical knowledge of China. It is lived, practitioner-level authority.
03
360-Degree Expert Team
China risk does not respect disciplinary boundaries. Our specialist team covers technology, supply chain, regulatory, and national security — enabling us to give clients a single, integrated assessment across every dimension of a China-related decision, rather than requiring them to assemble multiple advisers and reconcile their findings themselves.
Practice Areas

Six capabilities.
One integrated
practice.

Every Fountainhead capability begins with Chinese-language primary sources. The analysis, legal interpretation, and strategic advice that follow are built on intelligence that clients cannot obtain anywhere else.

Partner & Target Screening

Institutional analysis of Chinese pharmaceutical and biotechnology entities — state ownership mapping, patent co-inventor audits, research institution affiliation screening — from primary sources, in Chinese.

Transaction Due Diligence

Pre-transaction analysis of Chinese counterparties for licensing, M&A, and joint venture transactions — covering ownership structures, state relationships, and regulatory risk invisible to English-language advisers.

Competitive Intelligence

Real-time monitoring of Chinese clinical trial registries, regulatory approvals, patent filings, corporate announcements, and deal activity — translated into competitive and investment intelligence for US and European pharmaceutical companies and financial institutions.

Supply Chain Risk Assessment

Systematic review of Chinese suppliers and service relationships within pharmaceutical supply chains — identifying state ownership structures, national security regulatory exposure, and transition requirements.

Geopolitical Risk Advisory

Structured intelligence and decision-grade advisory on China's regulatory trajectory, geopolitical risk, sanctions and trade control architecture, technology and supply chain strategy, and the political system factors that shape commercial outcomes. We advise boards, investment committees, and executive leadership on the strategic dimensions of China and Indo-Pacific risk — integrating scenario analysis, early-stage policy signal detection, and cross-jurisdictional risk mapping into a single, actionable assessment. This is not commentary. It is advisory grounded in primary-source intelligence and practitioner-level understanding of the PRC political and regulatory system.

Sanctions, Trade Controls & Regulatory Architecture

Advisory on the strategic and commercial implications of sanctions regimes, export controls, tariffs, and inbound investment screening — including CFIUS, BIOSECURE Act exposure, and supply chain regulatory risk. We help clients understand their exposure, map their options, and position their organisations for evolving trade and regulatory environments. All advisory is strategic in nature. Clients requiring legal counsel on specific regulatory matters are referred to appropriately licensed legal practitioners.

Executive Briefings

Senior advisory sessions combining PRC legal authority and sector expertise — designed for boards, C-suites, investment committees, and credit and risk committees at financial institutions requiring authoritative China assessment on a specific decision or transaction.

Engagements

Defined scope.
Predictable fees.

Every Fountainhead engagement produces a named deliverable with a defined scope, timeline, and fee. No ambiguity about what you are commissioning or what you will receive.

01
Chinese Partner
Due Diligence
Full institutional due diligence brief on a named Chinese pharmaceutical or biotechnology entity. Covers corporate ownership, state investor identification, patent co-inventor analysis, research institution affiliation screening, and national security regulatory risk. Standard delivery in 10–15 business days; expedited in 5.
02
Executive
Briefing Session
Half-day senior advisory session with Fountainhead's principal team — combining PRC legal authority with technology, supply chain, regulatory, and national security expertise. For boards, investment committees, credit and risk committees, or C-suite teams requiring authoritative China assessment on a specific decision, transaction, or counterparty.
03
China Pharma
Intelligence Bulletin
Quarterly subscription covering Chinese-language monitoring of drug regulator approvals, clinical trial registrations, patent applications, corporate registry changes, and competitive developments across China's pharmaceutical and biotechnology sector.
04
Supply Chain
Risk Audit
Systematic mapping and assessment of Chinese suppliers, equipment providers, and service relationships within a client's pharmaceutical or biotechnology supply chain — with state ownership analysis and a prioritised remediation roadmap.
05
Investment Risk
Assessment
China-specific risk assessment for financial institutions, private equity, and hedge funds evaluating investment exposure to Chinese-linked entities. Covers ownership and control structures, state affiliation, regulatory and political risk, and the specific factors that credit committees and investment committees require documented analysis on before approving China-exposed positions.
06
Strategic Competitive
Advisory
Bespoke mandate for corporations or financial institutions monitoring a specific Chinese entity or sector. Combines ongoing Chinese-language primary source monitoring with periodic analytical briefings on competitive positioning, pipeline developments, regulatory milestones, and ownership changes.
07
Geopolitical Risk
Retainer
Ongoing advisory relationship for boards, risk committees, and executive leadership requiring continuous monitoring of China and Indo-Pacific geopolitical developments. Includes monthly strategic briefings, on-call advisory access for time-sensitive decisions, quarterly scenario updates, and annual risk simulation. Structured as a confidential retainer with defined deliverables and response time commitments.
Leadership

Unique credentials.

Dennis Kwok
Founding Principal
Dennis Kwok
Former Member, Hong Kong Legislative Council (2012–2020)
Senior Fellow, Harvard Kennedy School (2021–2023) · Distinguished Scholar, Georgetown SFS (2021) · Northeastern University
Dennis Kwok has spent 25 years at the intersection of law, politics, and commercial life in China and Hong Kong — a depth of experience that is, in practical terms, unreplicable in the Western advisory market.

From 2012 to 2020, Dennis was elected by his peers as the sole representative of the legal profession in the Hong Kong Legislative Council. Whilst in public office, Dennis focused on defending the rule of law, freedom and advancing democracy in Hong Kong.

In recognition for his work in public office, Dennis is the recipient of the New York State Bar Association Award for Distinction in International Law and Affairs 2022, and the Commonwealth Law Conference Rule of Law Award 2021. He was appointed as a Senior Fellow of Harvard Kennedy School, Ash Centre from 2021 to 2023, and as a Distinguished Scholar at Georgetown University School of Foreign Service in 2021. He taught as a visiting Associate Professor at Tokyo University, and is currently a faculty affiliate at the Center for International Affairs and World Culture at Northeastern University.

Dennis has practised law with a focus on the Asia Pacific region for over 25 years. He began his legal career at the international firm Herbert Smith before developing a practice as a barrister in Hong Kong from 2006 to 2023, advising and representing international businesses in complex litigation, arbitration, and cross-border commercial transactions. He was lead counsel in major disputes concerning life sciences and pharmaceutical companies in China and APAC.

Dennis is the founder of the China Strategic Risks Institute, a London-based think tank which advises democratic governments around the world on China-related policies. It has a global team of advisors based in Europe, APAC, and North America.

He leads a team of China specialists whose collective expertise spans technology, supply chain, national security, and policy — enabling Fountainhead to deliver advice that is genuinely 360 degrees rather than narrow in scope, and is among the most credentialled China authorities available to the private sector.
360° Expert Coverage
The
Fountainhead Team
Technology · Supply Chain · Policy · National Security
Chinese-Language Primary Source Analysis
The Fountainhead team covers every dimension of China risk from a single point of contact. Our experts are based across the EU, North America, and Japan — each a leading authority in their field. Together, they span technology assessment, supply chain risk, regulatory analysis, and national security — enabling clients to receive integrated, 360-degree advice rather than disconnected inputs from multiple advisers they must reconcile themselves.

This geographic reach and disciplinary breadth means Fountainhead can mobilise the right expertise for any China-related question, regardless of where the client or the risk sits. Our team members bring deep practitioner experience from government, industry, and academia across three continents.

Underpinning the team's analytical work is a systematic intelligence capability: continuous monitoring and analysis of Chinese patent databases, drug regulator filings, clinical trial registries, corporate registry records, and institutional affiliation databases — in Chinese, before findings reach English-language analysts.
Technology Supply Chain National Security Regulatory Analysis Chinese IP Specialist Chinese-Language Intel
Why Fountainhead

The key questions for any
GC or Risk Committee to ask.

"Who invented this technology — and do any of the inventors have affiliations with state research institutions?"
This requires cross-referencing patent co-inventor records against state and military institution databases — in Chinese, and with a thorough understanding of how the PRC state operates. Fountainhead answers it as a matter of standard methodology.
"Is this Chinese investor a passive fund, or does it carry a state mandate that creates governance risk?"
State investor relationships are often invisible in published corporate materials and obscured through different entities. Fountainhead identifies these relationships routinely through its in-depth knowledge and intelligence in China.
"What is my Chinese competitor filing with regulators that they have not disclosed in English?"
Drug regulator approvals, clinical trial applications, and patent filings are public in Chinese — and almost never monitored systematically by Western intelligence teams. Fountainhead monitors them continuously.
"We are considering a significant investment in a Chinese-linked entity. What does our risk committee actually need to know?"
Credit committees, investment committees, and risk functions at banks and funds increasingly face China-exposure questions that their internal teams are not equipped to answer with primary-source rigour. Fountainhead provides the institutional analysis that gives risk committees the documented basis to decide.
"How does the PRC political system actually shape the regulatory and commercial risk we face?"
Generic commentary cannot answer this with the precision of a legal practitioner with direct PRC dispute and capital markets experience. That is what our founding principal brings.
"We are facing a sanctions or export control question with a China dimension. Who can actually advise us on the strategic implications — not just the legal compliance?"
Sanctions and trade control frameworks are increasingly geopolitical in character — they reflect strategic competition, not just regulatory policy. Understanding their strategic logic, their likely trajectory, and their implications for your business requires a practitioner who understands both the PRC political system and the Western regulatory architecture shaping the response. That is what Fountainhead provides. For legal compliance advice on specific regulatory matters, we work alongside appropriately licensed legal counsel.
Publications

25 years of analysis.
Published across the
leading platforms.

Dennis Kwok has written extensively on China and Hong Kong's political, legal, and regulatory trajectory — and on the strategic and commercial implications for international businesses, financial institutions, and governments. Selected publications below.

Wall Street Journal · The Diplomat · New York Law Journal · The Wire China · Harvard Kennedy School · Globe and Mail · Nikkei Asia · Taiwan Insight · SOAS China Institute
STAT News
"China's Strict New Supply Chain Regulations Could Create Massive Problems for Western Biopharma Companies"
On Decree No. 834, granting Beijing sweeping powers to investigate and sanction foreign companies whose decisions harm China's industrial chain security — and what it means for biotech and pharmaceutical firms as Beijing protects sectors designated in its 15th Five-Year Plan. May 2026.
Wall Street Journal
"U.S.–China Audit Deal Is Only Window Dressing"
Co-authored with Sam Goodman on the U.S.–China audit inspection deal and what Hong Kong's post-1984 experience tells America about negotiating with Beijing. August 2022.
Wall Street Journal
"Hong Kong Listing Means More Trouble for Didi"
Co-authored with Charles Mok on the delisting of Didi Chuxing from the NYSE and the implications for Chinese technology companies seeking Western capital. December 2021.
The Diplomat
"Look to Hong Kong, Not Ukraine, For Signals About China's Taiwan Plans"
Co-authored with Johnny Patterson, on what Hong Kong's experience reveals about the trajectory of Beijing's posture toward Taipei. April 2022.
The Diplomat
"Nickel Short Saga Raises Questions About China's Interference in International Markets"
Co-authored with Sam Goodman, on the LME nickel crisis and the risks of authoritarian interference in international financial markets. March 2022.
The Diplomat
"China's Neo-Nationalism Poses Risks for International Businesses"
Co-authored with Charles Mok, on how Xi Jinping's ideological turn shapes the operating environment for foreign firms. November 2021.
The Diplomat
Op-eds on Canadian Pension Fund Exposure & U.K. Legal Establishment
With Sam Goodman on Canadian pension fund exposure to Chinese entities linked to human rights violations and forced labour, and on the U.K. legal establishment's continued reliance on a fictional version of the Hong Kong rule of law.
New York Law Journal
"Taiwan Strait: A Tipping Point for International Companies and Their Lawyers"
Co-authored with Mark Elliott and Angela Turturro, on the new legal and political risk for international companies operating in the China region in the event of conflict over the Taiwan Strait. May 2022.
The Wire China
"China, Japan and the Gift of Coercion"
Co-authored with Sam Goodman and Andrew Yeh, on why Beijing's attempt to punish Japan over Taiwan is a major strategic blunder that is likely to backfire. March 2026.
The Wire China
"Companies Need More Help With the Rules of the Trade War"
Co-authored with Sam Goodman, on the case for like-minded democratic governments to set up guardrails for firms hedging their bets between the U.S. and China. October 2025.
The Wire China
"Beijing's Port Predicament"
Co-authored with Sam Goodman, on the CK Hutchison–Panama Canal row and the message Beijing's intervention sends about the independence of Hong Kong companies. April 2025.
Harvard Kennedy School · Rajawali Institute
"The Inevitable End of 'One Country, Two Systems'"
On the future trajectory of the CCP as seen from Hong Kong.
Harvard Kennedy School · Ash Center
Risks for International Businesses Under the Hong Kong National Security Law
Research paper analysing the legal, political, and operational risks confronting international businesses operating under the Hong Kong National Security Law — and the implications for compliance, governance, and personnel exposure.
Harvard Kennedy School · Ash Center
Taiwan: Through the Lens of Hong Kong
Risk analysis over the Taiwan Strait through the lens of the Hong Kong experience — examining what Beijing's handling of Hong Kong reveals about its likely posture toward Taiwan, and the strategic implications for international companies, investors, and governments.
Globe and Mail · Canadian Investment Review · Nikkei Asia
Commentary on Canada–China Relations & ESG Standards
With Sam Goodman, on the consequences for Canadian and international companies of the Canada–China diplomatic rupture, and on the structural difficulties of applying ESG and human rights standards to Chinese stocks and bonds.
SOAS China Institute
Hong Kong's Status as an International Financial Hub
Analysis of how Xi Jinping's national security agenda has placed Hong Kong's status as an international financial hub on the edge of a precipice.
Get in Touch

Speak with
our team.

Engagements begin with a confidential conversation. Tell us the decision you are facing — we will tell you whether Fountainhead can help and on what timeline.

Coverage
Operating across Boston, New York,
and London
Practice
Life Sciences & Pharmaceutical
Financial Institutions & Investment Funds
Technology & Supply Chain
Discretion
All enquiries are strictly confidential.
We do not disclose client identities.